With funding in place, Spyryx CEO focused on Phase 2 trial

After raising $18 million in its Series A round back in 2015, Durham ’s Spyryx Biosciences is currently moving forward with a Phase 2 trial of its drug candidate SPX-101 in cystic fibrosis (CF) patients. Essentially, SPX-101 is designed to regulate airway hydration and enable mucociliary clearance in CF patients, according to the company. It has the potential to b e “applicable to all CF patients,” says Spyryx CEO John Taylor. Since raising $18 million from investors Canaan Partners, Hatteras…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news